Posted in | News | Nanomedicine | Nanoethics

First European Network of Excellence in Nanobiotechnology, Nano2Life, to Present Main Achievements

The first European network of excellence in nanobiotechnology, Nano2Life (N2L), will present its main achievements on February the 26th, 2008, in Brussels for stakeholders, EC representatives and the scientific community. The event will be at Stanhope Hotel, Rue du Commerce, 9, between 2:30-7:00 p.m.

After four years of operation, N2L has become the visible face of European nanobiotechnology and is the most active European network in this field. Founded in 2004 it comprises 23 major European R&D organisations from 12 countries and 30 associated partners from industry and academia. N2L will highlight at this event its scientific, technological, educational, ethical and human resources-linked achievements obtained during four years of collaboration.

A poster show and invited key-note speakers will present all facets of the network initiated joint research collaborations, technology transfer, gender, IPR and the innovative and inspiring the so famous "N2L - spirit".

The meeting will be the platform to discuss the importance of such an European nanobiotechnology community in order to face the competitive challenges from the US and/or Japan. Lessons from the past, success and failures will help the design of the future European capacity in nanobiotechnology and nanomedicine.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.